High-Throughput Drug Discovery Using AstraZeneca's Screening Facilities

This funding opportunity enables academic researchers to advance early-stage drug discovery by accessing AstraZeneca's extensive compound library containing over two million molecules and world-class high-throughput screening (HTS) equipment. Selected projects gain hands-on access to cutting-edge screening capabilities to identify promising lead compounds for small molecule pharmaceutical development. The program funds up to four projects annually, with grants of up to £270,000 per award. Projects typically run for 12-18 months (standard duration 15 months). This initiative bridges academic research and industry innovation, providing researchers with resources that would otherwise be unavailable in academic settings. Successful applicants should have clearly defined screening objectives and the capability to evaluate results for further drug development.